Skip to main content
. 2021 Dec 6;12:788558. doi: 10.3389/fphar.2021.788558

FIGURE 7.

FIGURE 7

UDCA protects against intestinal barrier disruption and reduces serum LPS and inflammatory cytokines in NASH mice. (A) H&E staining of mouse intestinal tissue from ND-control, HFHC-control and HFHD-UDCA (120 mg/kg) group. (B) Comparison of the Chiu score for mouse intestinal tissue from ND-control, HFHC-control, and HFHD-UDCA (120 mg/kg) groups. (C) Immunohistochemistry staining for ZO-1 and Claudin-1 expression in the mouse intestine from ND-control, HFHC-control, and HFHD-UDCA (120 mg/kg) groups. (D) Comparison of H-score for the immunohistochemical evaluation of ZO-1 and Claudin-1 expression in the mouse intestine from ND-control, HFHC-control, and HFHD-UDCA (120 mg/kg) groups. (E) UDCA treatment reduces serum LPS and inflammatory cytokines in NASH mice. Values represent mean ± standard deviation with *p < 0.05, **p < 0.01, ***p < 0.001 and ns vs HFHC-control group. Abbreviation: UDCA, ursodeoxycholic acid; LPS, lipopolysaccharide; NASH, non-alcoholic steatohepatitis; HFHC, high-fat high-cholesterol; ND, normal diet; ns, not significant.